KRSA Korsana Biosciences, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

KRSA — —

What changed

Recent filings, trades and moves
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$1.4B
List Date
2026-09-09
CIK
0001755237
Last Earnings
Sep 11
Headquarters
Waltham, MA
Homepage
https://www.korsana.com

Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
Insufficient price history — listed 61 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Loading technical indicators...
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
All KRSA news →

KRSA Options Activity & IV Rank

Loading options activity...
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Insufficient price history — listed 61 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

KRSA Institutional Ownership (13F)

Filings for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

5 filers2,001,513 shares$64.05M value
# Filer Shares Value % of Total % of Float Period
1 Sanofi 1,994,011 $63.81M 99.63% — 2026-09-30
2 Geode Capital Management, LLC Custodian 7,476 $239.29K 0.37% — 2026-09-30
3 Activest Wealth Management 14 $448 <0.01% — 2026-09-30
4 Citigroup Inc. Custodian 11 $352 <0.01% — 2026-09-30
5 Caitong International Asset Management Co., Ltd 1 $32 0.00% — 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

KRSA Insider Trading (Form 4)

Latest: 2026-09-10
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-10 Andrew Gottesdiener Director Grant (A) +48,445 opt — EDGAR
2026-09-10 Michelle Patricia Pernice Director Grant (A) +48,445 opt — EDGAR
2026-09-10 Nimish P Shah Director Grant (A) +48,445 opt — EDGAR
2026-09-10 Fairmount Healthcare Fund II L.P. Director Grant (A) +48,445 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

KRSA Board & Officers

As of SEC filings through Sep 10, 2026

Directors 15

Officers 4

  • Regina Margaret Graul · President and Chief Executive Officer · listed since Aug 2024
  • Mark J. Vignola · Chief Financial Officer · since Sep 8, 2026
  • Matthew James Leoni · Chief Medical Officer · since Sep 8, 2026
  • Jonathan Violin · since Sep 8, 2026

10% owners 6

Changes in the last 10 years (61)
Sep 8, 2026Tomas Kiselak became a director
Sep 8, 2026Tomas Kiselak became a 10% owner
Sep 8, 2026The company announced the departure of Rhonda M. Chicko as Chief Financial Officer in an SEC filing
Sep 8, 2026Peter Evan Harwin became a director
Sep 8, 2026Peter Evan Harwin became a 10% owner
Sep 8, 2026Nimish P Shah became a director
Sep 8, 2026Michelle Patricia Pernice became a director
Sep 8, 2026Matthew James Leoni became Chief Medical Officer
Sep 8, 2026Mark J. Vignola became Chief Financial Officer
Sep 8, 2026Jonathan Violin became an officer
Sep 8, 2026Jonathan Violin became a director
Sep 8, 2026Heidi Henson became a director
Sep 8, 2026Fairmount Healthcare Fund II L.P. became a director
Sep 8, 2026Fairmount Healthcare Fund II L.P. became a 10% owner
Sep 8, 2026Fairmount Healthcare Co-Invest VI L.P. became a director
Sep 8, 2026Fairmount Healthcare Co-Invest VI L.P. became a 10% owner
Sep 8, 2026Fairmount Funds Management LLC became a director
Sep 8, 2026Fairmount Funds Management LLC became a 10% owner
Sep 8, 2026Andrew Gottesdiener became a director
Nov 25, 2024Slate Path Capital LP reported in an SEC filing no longer being a 10% owner
Not reported recently (12)
  • Terrance McGuire · Last reported as a director in an SEC filing dated Dec 4, 2023
  • Errol B Desouza · Last reported as a director in an SEC filing dated Dec 4, 2023
  • Marsha Fanucci · Last reported as a director in an SEC filing dated Jun 16, 2022
  • Michael Mendelsohn · Last reported as a director in an SEC filing dated Jun 16, 2022
  • Stephanie Lovell · Last reported as a director in an SEC filing dated Jun 16, 2022
  • Anjeza Gjino · Last reported as Chief Financial Officer in an SEC filing dated Jan 24, 2022
  • Kevin Churchwell · Last reported as a director in an SEC filing dated Jun 28, 2021
  • Christopher I Wright · Last reported as Chief Medical Officer in an SEC filing dated Mar 1, 2021
  • Mark G Currie · Last reported as President in an SEC filing dated Dec 30, 2020
  • William Huyett · Last reported as Chief Financial Officer in an SEC filing dated Nov 10, 2020
  • Amy W Schulman · Last reported as a director in an SEC filing dated Jun 18, 2020
  • Gina Consylman · Last reported as a director in an SEC filing dated Mar 14, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

KRSA Proposed Insider Sales (Form 144)

Latest: 2026-10-22
Last 30d: 1 filing · $35K notice value  ·  Last 90d: 4 filings · $285K notice value · 2 unique filers

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: ERROL B DE SOUZA (3, $250K) · MICHAEL HIGGINS (1, $35K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-22 MICHAEL HIGGINS Director 1,107 $35.4K 2026-10-22 Morgan Stanley Smith Barney LLC … — EDGAR
2026-09-23 ERROL B DE SOUZA Director 4,903 $171.6K 2026-09-23 Morgan Stanley Smith Barney LLC … — EDGAR
2026-09-22 ERROL B DE SOUZA Director 100 $3.5K 2026-09-22 Morgan Stanley Smith Barney LLC … — EDGAR
2026-09-18 ERROL B DE SOUZA Director 2,139 $74.8K 2026-09-18 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-05 Earnings results EDGAR
2026-09-11 Material agreement · Acquisition or sale completed · Earnings results · Unregistered share sale · Shareholder rights change · Change in control · Director or officer change · Bylaws or fiscal year change · Code of ethics change · Shell company status change · Regulation FD disclosure EDGAR
2026-08-27 Shareholder vote results · Other events EDGAR
2026-08-25 Other events EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-05 0001193125-26-448636 EDGAR
2026-08-04 0001193125-26-332842 EDGAR
ETF Holders
6 ETFs hold KRSA
6 shown · $276.82K total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $141,312 — 2026-09-30
2 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $94,059 $10.0B 2026-11-05
3 DFSU Dimensional US Sustainability Core 1 ETF Dimensional 0.00% $14,424 $2.3B 2026-11-05
4 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $14,302 — 2026-11-05
5 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $9,494 — 2026-11-05
6 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $3,226 — 2026-11-05
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

KRSA vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 46.0 +45.5% +31.2% 25
JNJ Johnson & Johnson $664.9B 42.9 +7.8% +36.3% 58
ABBV ABBVIE INC. $514.9B 50.3 +10.7% +27.5% 37
MRK Merck & Co., Inc. $361.7B 153.2 +4.9% +39.6% 45
NVS Novartis AG $307.0B — — +18.5% 38
AZN AstraZeneca PLC $289.1B — — +107.1% 0
ABT Abbott Laboratories $190.4B 40.9 +10.0% −11.1% 19
NVO Novo-Nordisk A/S $177.7B — — −20.6% 18
KRSA Korsana Biosciences, Inc. Common Stock $1.4B — — — —
Peer median $334.4B 46.0 +10.0% +29.4% 31

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.